These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. Ciofu O APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154 [TBL] [Abstract][Full Text] [Related]
3. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. Meluleni GJ; Grout M; Evans DJ; Pier GB J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254 [TBL] [Abstract][Full Text] [Related]
4. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. Ciofu O; Mandsberg LF; Wang H; Høiby N FEMS Immunol Med Microbiol; 2012 Jul; 65(2):215-25. PubMed ID: 22540844 [TBL] [Abstract][Full Text] [Related]
5. [Investigation of biofilm formation and relationship with genotype and antibiotic susceptibility of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis]. Coban AY; Ciftci A; Onuk EE; Erturan Z; Tanriverdi Cayci Y; Durupinar B Mikrobiyol Bul; 2009 Oct; 43(4):563-73. PubMed ID: 20084909 [TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Murray TS; Egan M; Kazmierczak BI Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667 [TBL] [Abstract][Full Text] [Related]
7. [Foreign body infections--biofilms and quorum sensing]. Høiby N; Johansen HK; Ciofu O; Jensen PØ; Bjarnsholt T; Givskov M Ugeskr Laeger; 2007 Nov; 169(48):4163-6. PubMed ID: 18211783 [TBL] [Abstract][Full Text] [Related]
8. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967 [TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Bjarnsholt T; Jensen PØ; Fiandaca MJ; Pedersen J; Hansen CR; Andersen CB; Pressler T; Givskov M; Høiby N Pediatr Pulmonol; 2009 Jun; 44(6):547-58. PubMed ID: 19418571 [TBL] [Abstract][Full Text] [Related]
13. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle. Johansen HK; Cryz SJ; Hougen HP; Moser C; Høiby N Behring Inst Mitt; 1997 Feb; (98):269-73. PubMed ID: 9382750 [TBL] [Abstract][Full Text] [Related]
14. How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis? VanDevanter DR; Van Dalfsen JM Pediatr Pulmonol; 2005 Jun; 39(6):504-6. PubMed ID: 15830388 [TBL] [Abstract][Full Text] [Related]
15. Anaerobic culture conditions favor biofilm-like phenotypes in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. O'May CY; Reid DW; Kirov SM FEMS Immunol Med Microbiol; 2006 Dec; 48(3):373-80. PubMed ID: 17052266 [TBL] [Abstract][Full Text] [Related]
16. Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients. Lee B; Schjerling CK; Kirkby N; Hoffmann N; Borup R; Molin S; Høiby N; Ciofu O APMIS; 2011 Apr; 119(4-5):263-74. PubMed ID: 21492226 [TBL] [Abstract][Full Text] [Related]
17. Characterization of clonal strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Ontario, Canada. Beaudoin T; Aaron SD; Giesbrecht-Lewis T; Vandemheen K; Mah TF Can J Microbiol; 2010 Jul; 56(7):548-57. PubMed ID: 20651854 [TBL] [Abstract][Full Text] [Related]
18. Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Ramsey DM; Wozniak DJ Mol Microbiol; 2005 Apr; 56(2):309-22. PubMed ID: 15813726 [TBL] [Abstract][Full Text] [Related]
19. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients. Pier GB Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760 [TBL] [Abstract][Full Text] [Related]
20. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Hogardt M; Heesemann J Int J Med Microbiol; 2010 Dec; 300(8):557-62. PubMed ID: 20943439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]